Work

ABCL-674: A Phase 1 Trial of NX-2127, a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients With Relapsed/Refractory B-cell Malignancies

Year: 2025

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)02284-0

Authors: Alexey Danilov, Michael Tees, Harsh Shah, Clare Sun, Ian Flinn, Daniel Ermann, Jason Westin, Michael Thirman, Melannie Co, Amanda Schwab, Carolina Ryklansky, May Tan, Erin Meredith, Adrian Wiestner

Institutions: City Of Hope National Medical Center, Colorado Blood Cancer Institute, Huntsman Cancer Institute, National Institutes of Health, National Heart, Lung, and Blood Institute, Tennessee Oncology, The University of Texas MD Anderson Cancer Center, University of Chicago, Nurix (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413783201

FWCI:

Cites:

Cited by:

Related to: 10